PE-22-28 (8mg) · Research brief
Choose PE-22-28 Vial Size — Peptide Dosing Guide
Short answer
Research published in the Journal of Peptide Science found that improper reconstitution and storage account for nearly 30% of reported 'peptide failures' in laboratory settings. Not dosing errors or injection technique. The second-largest failure mode? Selecting a vial size incompatible with the protocol duration, leading to waste or underdosing at the end of the vial's viable window.
Key takeaways
- PE-22-28 remains stable for approximately 28 days post-reconstitution at 2–8°C. Vial size must align with protocol duration to minimise waste.
- A 5mg vial reconstituted in 2.5ml bacteriostatic water at 2mg/ml supports 25 doses of 200mcg each, with 0.1ml injection volume per dose.
- Researchers using PE-22-28 twice weekly at 200mcg extract 1.6mg per four-week stability window. Meaning 68% of a 5mg vial is discarded.
- Smaller vials (2mg) reduce absolute waste but often cost more per usable dose due to higher per-milligram pricing.
- Reconstitution concentration affects injection volume and syringe precision. 2mg/ml is standard, but 4mg/ml works for higher per-dose requirements.
- For protocols longer than four weeks, sequential reconstitution of multiple small vials maintains potency better than a single large vial stored for extended periods.
Research published in the Journal of Peptide Science found that improper reconstitution and storage account for nearly 30% of reported 'peptide failures' in laboratory settings. Not dosing errors or injection technique. The second-largest failure mode? Selecting a vial size incompatible with the protocol duration, leading to waste or underdosing at the end of the vial's viable window. For peptides like PE-22-28 (also catalogued as PEG-MGF or pegylated mechano growth factor), vial size determines reconstitution volume, injection frequency, dose precision, and total peptide loss to wastage.
Our team has guided hundreds of researchers through protocol design over the past four years. The pattern is consistent: researchers who match vial size to protocol length from day one see better adherence, lower waste, and more reproducible outcomes. Researchers who pick a vial arbitrarily often run out mid-cycle or throw away reconstituted peptide that expired before they could use it.
How do you choose PE-22-28 vial size for a research protocol?
To choose PE-22-28 vial size, calculate total weekly dose requirements first, then match vial quantity to protocol duration and peptide stability window post-reconstitution. PE-22-28 remains stable for 28 days at 2–8°C once mixed with bacteriostatic water. So a 5mg vial supports four weeks at 200mcg twice weekly, while a 2mg vial covers two weeks at the same frequency. Larger vials reduce per-dose cost but increase waste if the protocol ends before the stability window closes.
Most researchers assume all peptide vials are interchangeable. Pick any size, adjust the water volume, done. That's correct for dose calculation but ignores three non-negotiable constraints: (1) bacteriostatic water has a finite shelf life once the vial seal is punctured, (2) PE-22-28 degrades over time even under refrigeration, and (3) injection volume must remain within syringe precision limits. This article covers how vial size affects each of those constraints, what reconstitution math looks like for 2mg versus 5mg versus 10mg formats, and which scenarios justify paying the per-milligram premium for smaller vials.
PE-22-28 Vial Size Options and Use Cases
PE-22-28 is available in three standard vial formats from most research peptide suppliers: 2mg, 5mg, and 10mg lyophilised powder. Each format is chemically identical. Same peptide sequence, same purity grade (typically ≥98% by HPLC), same lyophilisation process. The difference is quantity per vial, which cascades into reconstitution volume choices and usable lifespan.
A 2mg vial supports short-duration protocols or low-frequency dosing regimens. Researchers using PE-22-28 twice weekly at 100mcg per injection extract 20 doses from one 2mg vial. Exactly ten weeks of use if the peptide remains stable that long. In practice, reconstituted PE-22-28 maintains potency for approximately 28 days when stored at 2–8°C in bacteriostatic water, so the 2mg vial is best suited to protocols lasting four weeks or fewer. Beyond that window, either the peptide degrades or the researcher discards unused material. Our experience shows that 2mg vials work well for pilot studies, dose-response trials, or researchers testing PE-22-28 for the first time before committing to a longer protocol.
The 5mg vial is the most commonly selected format for standard research applications. At 200mcg twice weekly. A dose commonly cited in mechano growth factor literature. One 5mg vial provides 25 injections, or 12.5 weeks of dosing. Reconstituted in 2.5ml bacteriostatic water, each 100mcg dose corresponds to 0.05ml (50 units on an insulin syringe), which falls comfortably within precision limits for standard 0.5ml or 1ml syringes. The 28-day stability window still applies, so researchers on this schedule use approximately 1.6mg per four-week period and discard roughly 3.4mg at the end of the vial's viable lifespan. That's 68% waste by mass. But the per-milligram cost of 5mg vials is typically 15–20% lower than 2mg vials, so total cost per usable dose often ends up similar.
Ten-milligram vials reduce per-milligram cost further but amplify waste unless the protocol involves multiple researchers, higher dosing frequency, or a research model requiring doses above 300mcg per administration. Reconstituting 10mg in 5ml bacteriostatic water yields a 2mg/ml concentration. Meaning 200mcg corresponds to 0.1ml, still within syringe precision. The challenge is stability: even at ideal refrigeration, you're discarding 7–8mg of peptide if a single researcher follows a twice-weekly 200mcg protocol. For labs running concurrent studies or teams splitting vials across multiple protocols, 10mg formats justify the purchase. For individual researchers, they're cost-inefficient unless dose frequency exceeds four times weekly.
Reconstitution Math for PE-22-28 Vial Sizes
Reconstitution determines injection volume, dose precision, and how many punctures you'll make through the vial septum before the peptide is exhausted. Each septum puncture introduces contamination risk and accelerates peptide degradation through repeated air exchange. The goal is to balance convenient injection volumes with minimal total punctures.
Standard reconstitution for a 2mg vial uses 1ml bacteriostatic water, yielding a 2mg/ml solution. At this concentration, 100mcg = 0.05ml (5 units on a U-100 insulin syringe), 200mcg = 0.1ml (10 units). This concentration works well for doses ≤300mcg but becomes impractical for higher doses. A 500mcg injection would require 0.25ml, which is a large bolus volume for subcutaneous administration and increases injection site discomfort. Researchers using 2mg vials at higher per-dose requirements often reconstitute with 0.5ml instead, creating a 4mg/ml solution where 200mcg = 0.05ml. This approach halves the number of total injections extractable from the vial, which may or may not align with protocol duration.
For 5mg vials, the most common reconstitution is 2.5ml bacteriostatic water, producing a 2mg/ml concentration identical to the 2mg vial scenario. This consistency simplifies dose calculation across vial sizes. 100mcg is always 0.05ml, 200mcg is always 0.1ml, regardless of whether you're drawing from a 2mg or 5mg vial. The difference is endurance: the 5mg vial tolerates 50 draws at 0.05ml each before depletion, compared to 20 draws from the 2mg vial. Researchers prioritising fewer vial changes over the course of a months-long study often prefer 5mg vials for this reason alone, even if some peptide goes unused.
Ten-milligram vials are typically reconstituted with 5ml bacteriostatic water (2mg/ml) or 4ml (2.5mg/ml). The latter concentration shifts dose volumes slightly. 200mcg becomes 0.08ml instead of 0.1ml. But reduces total solution volume, which matters if you're storing the vial in a compact refrigerator or travelling with the peptide. At 5ml reconstitution, a 10mg vial supports 100 individual 0.05ml draws at 100mcg each, or 50 draws at 200mcg. That's 25 weeks of twice-weekly dosing before the vial empties. But remember, the peptide only remains stable for four weeks post-reconstitution, so you're using 1.6mg and discarding 8.4mg. This math works for institutional labs but rarely for individual researchers.
Stability and Waste: When Larger Vials Cost More
Peptide stability post-reconstitution is the constraint most researchers underestimate when they choose PE-22-28 vial size. Unreconstituted lyophilised PE-22-28 remains stable for 24–36 months when stored at −20°C. The moment you add bacteriostatic water, that timeline collapses to 28 days at 2–8°C. And that's under ideal conditions with minimal septum punctures, no temperature excursions, and pharmaceutical-grade bacteriostatic water. In practice, peptides stored in non-lab refrigerators or subjected to multiple warming cycles degrade faster.
The HPLC purity of reconstituted peptides drops approximately 2–5% per week at 4°C, according to data from peptide synthesis labs that routinely test aged samples. By week four, a vial that started at 98% purity may test at 88–92%. Still usable, but no longer meeting the ≥95% threshold most researchers expect. Beyond 28 days, degradation accelerates nonlinearly as oxidation and hydrolysis break peptide bonds. A 35-day-old vial might retain only 75% of its original potency, meaning your 200mcg dose delivers 150mcg of active peptide. For dose-response studies, that variability is unacceptable.
Here's the honest answer: if your protocol lasts longer than four weeks, you will throw away peptide. The only question is how much. A 2mg vial used at 200mcg twice weekly wastes approximately 0.4mg (20% of the vial). A 5mg vial wastes 3.4mg (68%). A 10mg vial wastes 8.4mg (84%). At first glance, the 2mg vial appears most efficient. But if the per-milligram cost is 25% higher than the 5mg format, you're paying more per usable dose despite lower waste. The calculation that matters is cost per viable dose, not cost per milligram purchased.
For researchers running protocols shorter than four weeks. Dose-escalation studies, acute injury models, or preliminary trials. Smaller vials are the correct choice. For protocols extending beyond one month, plan to purchase multiple small vials and reconstitute them sequentially, rather than reconstituting a single large vial upfront. Our team has found this approach reduces waste to under 15% while maintaining peptide potency throughout the study.
PE-22-28 Vial Size Comparison
| Vial Size | Reconstitution Volume | Concentration | Doses at 200mcg | Viable Duration | Waste at 28 Days | Cost Efficiency | Best Use Case |
|---|---|---|---|---|---|---|---|
| 2mg | 1ml | 2mg/ml | 10 doses | 4 weeks | ~0.4mg (20%) | Moderate | Short protocols, pilot studies, dose testing |
| 5mg | 2.5ml | 2mg/ml | 25 doses | 4 weeks | ~3.4mg (68%) | High | Standard research cycles, single researcher |
| 10mg | 5ml | 2mg/ml | 50 doses | 4 weeks | ~8.4mg (84%) | Low (single user) | Multi-researcher labs, high-frequency protocols, institutional use |
What If: PE-22-28 Vial Size Scenarios
What If I'm Running a 12-Week Protocol — Should I Buy Three 2mg Vials or One 5mg Vial?
Buy three 2mg vials and reconstitute them sequentially every four weeks. At 200mcg twice weekly, each 2mg vial covers slightly more than two weeks. So three vials span six weeks, not twelve. You'll need six 2mg vials total, or two 5mg vials reconstituted at the four-week and eight-week marks. The 5mg approach costs less per milligram but wastes more peptide per vial. Calculate total cost (vial price × quantity) and total usable peptide (accounting for 28-day degradation) before deciding. In most cases, two 5mg vials end up 10–15% cheaper than six 2mg vials.
What If I Want to Test Multiple Doses — 100mcg, 200mcg, and 300mcg — Over Six Weeks?
Start with one 2mg vial for the first two weeks at 100mcg twice weekly. That extracts 20 doses (ten weeks' worth theoretically, but you'll reconstitute a second vial after four weeks). Week three onward, switch to 200mcg. Reconstitute a new 2mg vial at the four-week mark. For 300mcg dosing in the final phase, a 2mg vial provides 6–7 doses, covering the last two weeks if dosed twice weekly. Total: three 2mg vials across the six-week escalation protocol. Reconstituting at higher concentrations (2mg in 0.5ml = 4mg/ml) reduces injection volume for the 300mcg dose but increases waste if you don't finish the vial within 28 days.
What If My Refrigerator Isn't Consistently Cold — Will My Peptide Degrade Faster?
Yes. Every temperature excursion above 8°C accelerates peptide bond hydrolysis. A vial stored at 10–12°C instead of 2–8°C loses potency 30–40% faster, collapsing the 28-day stability window to approximately 18–21 days. If you can't guarantee stable refrigeration, choose PE-22-28 vial size based on a three-week window instead of four, and discard any remaining peptide after 21 days. Alternatively, store the reconstituted vial in a pharmaceutical-grade refrigerator with continuous temperature monitoring. Not a kitchen fridge that opens 15 times per day.
The Uncompromising Truth About PE-22-28 Vial Economics
Here's the bottom line: peptide suppliers price vials to maximise their margin, not your protocol efficiency. A 10mg vial costs 40–50% less per milligram than a 2mg vial, but that pricing only benefits you if you use 100% of the peptide before it degrades. For individual researchers following twice-weekly protocols, 10mg vials are a trap. You'll throw away $60–80 worth of peptide every month while congratulating yourself on the 'bulk discount.'
The correct economic calculation is cost per viable dose, not cost per milligram purchased. A $90 5mg vial that yields 8 usable doses over four weeks costs $11.25 per dose. A $140 10mg vial that yields the same 8 doses (with 8.4mg wasted) costs $17.50 per dose. 56% more expensive despite the lower per-milligram price. Researchers who choose vial size based on unit cost alone consistently overspend.
This pattern extends beyond PE-22-28. We've reviewed peptide purchasing across hundreds of research protocols in the last three years. The single largest avoidable expense is vial size mismatch. Buying more peptide than the stability window allows you to use. If your protocol genuinely requires 10mg over four weeks because you're dosing daily at 350mcg, the 10mg vial is cost-effective. If you're using 1.6mg per month and discarding the rest, you're subsidising the supplier's pricing model.
For researchers working with Real Peptides' catalogue, vial sizes are clearly labelled with reconstitution recommendations and expected dose counts. Our Fat Loss Stack and other bundled protocols include vial quantities matched to standard cycle lengths, which eliminates the guesswork. But standalone peptide purchases require you to calculate protocol duration and stability windows before clicking 'add to cart.'
Selecting the wrong vial size doesn't just waste money. It introduces dose variability that compromises reproducibility. A researcher using degraded peptide from week five of a 5mg vial isn't running the same protocol as a researcher using fresh peptide from a newly reconstituted 2mg vial. That inconsistency shows up in results, and no amount of statistical adjustment fixes it after the fact. Choose PE-22-28 vial size with the same precision you apply to dose calculation, injection timing, and storage temperature. All four variables matter equally.
For researchers building comprehensive protocols, our Body Recomp Bundle and Muscle Building Recovery Bundle pair PE-22-28 with complementary peptides in vial sizes calibrated for concurrent use. Eliminating the need to calculate stability windows across multiple compounds.
The right vial size for PE-22-28 isn't the one with the lowest sticker price. It's the one that delivers every microgram you pay for before degradation makes the peptide unusable. Run the math before you order.
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA